Red Light Holland Corp. News Releases

Red Light Holland Announces Shareholder Approval of Name Change and Announces Voting Results from 2026 Annual General and Special Meeting of Shareholders

Wed, 13 May 2026 09:12:00 -0400

Toronto, Ontario--(Newsfile Corp. - May 13, 2026) - Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) (FSE: 4YX) ("Red Light Holland" or the "Company") is pleased to announce that shareholders overwhelmingly approved the Company's proposed corporate name change at the Company's annual general and special meeting of shareholders ("Shareholders") held on Monday, May 11, 2026 at the Company's office in Toronto (the "Meeting").The special resolution approving the Company's proposed name change...

Red Light Holland Highlights Publication of Randomized Clinical Trial Showing a Single Dose of Psilocybin Reduced Cocaine Use, with Filament Health Holding the Exclusive License to the Data and Intellectual Property

Fri, 08 May 2026 07:30:00 -0400

Peer-reviewed results published yesterday (May 7, 2026) in JAMA Network Open demonstrate that a single dose of psilocybin meaningfully reduced cocaine use in adults with cocaine use disorder over six months, with no serious adverse eventsFilament Health Corp., a wholly-owned subsidiary of Red Light Holland, holds the exclusive worldwide license to the trial data and certain associated intellectual property, with the goal of supporting future regulatory authorizationFilament's lead botanical...

Red Light Holland's Wholly Owned Subsidiary, Filament Health, Expands Distribution of PEX010 Across Canadian and U.S. Research Institutions

Thu, 07 May 2026 07:30:00 -0400

Toronto, Ontario--(Newsfile Corp. - May 7, 2026) - Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) (FSE: 4YX) ("Red Light" or the "Company") is an Ontario-based organization advancing innovation and research within the legal psychedelic sector. Following its acquisition of Filament Health Corp. ("Filament"), the Company has expanded its pharmaceutical-grade manufacturing, regulatory, and clinical research capabilities, supporting the advancement of naturally derived psilocybin development and...

Red Light Holland Announces Intention to Rebrand

Mon, 04 May 2026 08:30:00 -0400

New name and branding to be announced in the coming weeks, better aligned with the Company's scientific mandate and all business segmentsName change resolution to be voted on by shareholders at the upcoming Annual General and Special Meeting ("AGSM") on May 11, 2026Company urges all shareholders to vote IN FAVOUR of the name change resolution to support the rebranding exerciseRebranding reflects the combined focus on clinical research, GMP manufacturing, FDA-aligned drug development, and the...

Red Light Holland Completes Acquisition of Filament Health, Creating a Global Leader in Psychedelic Drug Development, Commercialization and Distribution

Thu, 30 Apr 2026 07:30:00 -0400

Establishes a vertically integrated platform spanning pharmaceutical-grade botanical drug development and global consumer distributionAdds Filament's extensive intellectual property portfolio, including 70+ patents and proprietary extraction technologiesLeverages Health Canada Dealer's License and FDA-aligned clinical development pathways, including IND-enabled activitiesPositions the Company at the forefront of the rapidly emerging regulated psychedelic medicine industryAdvances clinical...

Red Light Holland Announces Filament Health Obtains Final Order for Proposed Arrangement

Wed, 29 Apr 2026 07:30:00 -0400

Toronto, Ontario--(Newsfile Corp. - April 29, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light" or the "Company") and Filament Health Corp. (OTC: FLHLF) ("Filament") are pleased to announce that, further to their joint press release dated March 10, 2026, March 23, 2026 and April 27, 2026, that the Supreme Court of British Columbia has issued a final order (the "Final Order") approving the previously announced acquisition by Red Light of all the issued and...

Red Light Holland Announces Filament Health Shareholder Approval of Acquisition

Mon, 27 Apr 2026 07:30:00 -0400

Toronto, Ontario--(Newsfile Corp. - April 27, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light") and Filament Health Corp. (OTC: FLHLF) ("Filament") are pleased to announce that, further to their joint press release dated March 10, 2026 and March 23, 2026, Filament's shareholders (the "Filament Shareholders") have approved each of the matters voted on at the Filament annual general and special meeting ("Filament Meeting") held on April 24, 2026, including...

Red Light Holland Showcases Growing Clinical Demand for Filament Health's PEX010 with New and Repeat University Shipments

Fri, 24 Apr 2026 08:26:00 -0400

Toronto, Ontario--(Newsfile Corp. - April 24, 2026) - Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) (FSE: 4YX) ("Red Light" or the "Company") is pleased to highlight continued expansion and execution of clinical supply shipments of PEX010, a botanical psilocybin drug candidate developed by Filament Health Corp., to leading Canadian research institutions.Following its press release dated April 7, 2026, Red Light is highlighting recent accomplishments and ongoing momentum, including completed...

Red Light Holland Highlights U.S. FDA-Authorized Study Supporting Multi-Session Psilocybin Therapy using Filament Health's Patented PEX010 Botanical Drug Candidate

Mon, 20 Apr 2026 07:30:00 -0400

Study conducted under U.S. FDA Investigational New Drug (IND) authorization by Dr. Anthony Back at the University of WashingtonSecond psilocybin session showed meaningful improvements in anxiety, depression, and overall psychological outcomes, with effects lasting up to 24 weeks69% of participants fell below clinical thresholds for anxiety and depression after second treatmentResearch builds on prior studies utilizing Filament's botanical psilocybin drug candidate, PEX010No serious adverse...

Red Light Holland Reports Continued Expansion of Filament Health's PEX010 Clinical Network with New License Agreements and Research Shipments

Tue, 07 Apr 2026 07:30:00 -0400

Three new license agreements signed and two research shipments completed in March 2026, spanning institutions in Australia, the United Kingdom, and CanadaToronto, Ontario--(Newsfile Corp. - April 7, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light" or the "Company") today announced that Filament Health Corp. ("Filament") signed three new license agreements and completed two research shipments during March 2026, further expanding the global clinical network for...